Skip to main content
Top
Published in: Nutrition Journal 1/2010

Open Access 01-12-2010 | Research

No significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year

Authors: Rolf Jorde, Monica Sneve, Peter A Torjesen, Yngve Figenschau, John-Bjarne Hansen, Guri Grimnes

Published in: Nutrition Journal | Issue 1/2010

Login to get access

Abstract

Background

In meta-analyses supplementation with vitamin D appears to reduce incidence of fractures, and in cross-sectional studies there is a positive association between serum 25-hydroxyvitamin D (25(OH)D) levels and bone mineral density (BMD). However, the effect of supplementation with high doses of vitamin D on BMD is more uncertain and could in theory have both positive and negative effects.

Methods

The study was a one year, double blind placebo-controlled intervention trial performed at the University Hospital of North Norway. 421 subjects, 21 - 70 years old, were included and 312 completed the study. The subjects were randomized to vitamin D3 40.000 IU per week (DD group), vitamin D3 20.000 IU per week (DP group), or placebo (PP group). All subjects were given 500 mg calcium daily. Serum 25(OH)D, osteoprotegrin (OPG), receptoractivator of nuclear factor-kappaB ligand (RANKL), and BMD at the lumbar spine and the hip were measured before and at the end of the study.

Results

At baseline the mean serum 25(OH)D levels were 58 nmol/L (all subjects) and increased to 141 and 100 nmol/L in the DD and DP groups, respectively. After one year, no significant differences were found between the three groups regarding change in BMD, serum OPG or RANKL.

Conclusions

Supplementation with high doses of vitamin D for one year does not appear to have a negative effect on BMD in healthy subjects. In order to disclose a positive effect, subjects with low BMD and/or low serum 25(OH)D levels need to be studied.

Trial registration

The trial was registered at ClinicalTrials.gov (NCT00243256).
Appendix
Available only for authorised users
Literature
1.
go back to reference DeLuca HF: Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004, 80: 1689S-1696S.PubMed DeLuca HF: Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004, 80: 1689S-1696S.PubMed
2.
go back to reference Vega D, Maalouf NM, Sakhaee K: Clinical Review: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab. 2007, 92: 4514-4521. 10.1210/jc.2007-0646.CrossRefPubMed Vega D, Maalouf NM, Sakhaee K: Clinical Review: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab. 2007, 92: 4514-4521. 10.1210/jc.2007-0646.CrossRefPubMed
3.
go back to reference Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K: Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun. 1997, 234: 137-142. 10.1006/bbrc.1997.6603.CrossRefPubMed Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K: Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun. 1997, 234: 137-142. 10.1006/bbrc.1997.6603.CrossRefPubMed
4.
go back to reference Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997, 89: 309-319. 10.1016/S0092-8674(00)80209-3.CrossRefPubMed Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997, 89: 309-319. 10.1016/S0092-8674(00)80209-3.CrossRefPubMed
5.
go back to reference Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci. 1998, 95: 3597-3602. 10.1073/pnas.95.7.3597.CrossRefPubMedPubMedCentral Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci. 1998, 95: 3597-3602. 10.1073/pnas.95.7.3597.CrossRefPubMedPubMedCentral
6.
go back to reference Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998, 93: 165-176. 10.1016/S0092-8674(00)81569-X.CrossRefPubMed Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998, 93: 165-176. 10.1016/S0092-8674(00)81569-X.CrossRefPubMed
7.
8.
go back to reference Takasu H, Sugita A, Uchiyama Y, Katagiri N, Okazaki M, Ogata E, Ikeda K: c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs. J Clin Invest. 2006, 116: 528-535. 10.1172/JCI24742.CrossRefPubMedPubMedCentral Takasu H, Sugita A, Uchiyama Y, Katagiri N, Okazaki M, Ogata E, Ikeda K: c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs. J Clin Invest. 2006, 116: 528-535. 10.1172/JCI24742.CrossRefPubMedPubMedCentral
9.
go back to reference Baldock PA, Thomas GP, Hodge JM, Baker SU, Dressel U, O'Loughlin PD, Nicholson GC, Briffa KH, Eisman JA, Gardiner EM: Vitamin D action and regulation of bone remodeling: suppression of osteoclastogenesis by the mature osteoblast. J Bone Miner Res. 2006, 21: 1618-1626. 10.1359/jbmr.060714.CrossRefPubMed Baldock PA, Thomas GP, Hodge JM, Baker SU, Dressel U, O'Loughlin PD, Nicholson GC, Briffa KH, Eisman JA, Gardiner EM: Vitamin D action and regulation of bone remodeling: suppression of osteoclastogenesis by the mature osteoblast. J Bone Miner Res. 2006, 21: 1618-1626. 10.1359/jbmr.060714.CrossRefPubMed
10.
go back to reference Raisz LG, Trummel CL, Holick MF, DeLuca HF: 1,25-dihydroxycholecalciferol: a potent stimulator of bone resorption in tissue culture. Science. 1972, 175: 768-769. 10.1126/science.175.4023.768.CrossRefPubMed Raisz LG, Trummel CL, Holick MF, DeLuca HF: 1,25-dihydroxycholecalciferol: a potent stimulator of bone resorption in tissue culture. Science. 1972, 175: 768-769. 10.1126/science.175.4023.768.CrossRefPubMed
11.
go back to reference Ikeda K: Vitamin D, osteoclastogenesis and bone resorption: from mechanistic insight to the development of new analogs. Endocr J. 2007, 54: 1-6. 10.1507/endocrj.KR-82.CrossRefPubMed Ikeda K: Vitamin D, osteoclastogenesis and bone resorption: from mechanistic insight to the development of new analogs. Endocr J. 2007, 54: 1-6. 10.1507/endocrj.KR-82.CrossRefPubMed
12.
go back to reference Shiraishi A, Takeda S, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N, Sato K, Ikeda K, Nakamura T, Matsumoto T, Ogata E: Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res. 2000, 15: 770-779. 10.1359/jbmr.2000.15.4.770.CrossRefPubMed Shiraishi A, Takeda S, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N, Sato K, Ikeda K, Nakamura T, Matsumoto T, Ogata E: Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res. 2000, 15: 770-779. 10.1359/jbmr.2000.15.4.770.CrossRefPubMed
13.
go back to reference Bischoff-Ferrari HA, Willett WC, Wong JB, Stuck AE, Staehelin HB, Orav EJ, Thoma A, Kiel DP, Henschkowski J: Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med. 2009, 169: 551-561. 10.1001/archinternmed.2008.600.CrossRefPubMed Bischoff-Ferrari HA, Willett WC, Wong JB, Stuck AE, Staehelin HB, Orav EJ, Thoma A, Kiel DP, Henschkowski J: Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med. 2009, 169: 551-561. 10.1001/archinternmed.2008.600.CrossRefPubMed
14.
go back to reference Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B: Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med. 2004, 116: 634-639. 10.1016/j.amjmed.2003.12.029.CrossRefPubMed Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B: Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med. 2004, 116: 634-639. 10.1016/j.amjmed.2003.12.029.CrossRefPubMed
15.
go back to reference Vieth R, Bischoff-Ferrari H, Boucher BJ, Dawson-Hughes B, Garland CF, Heaney RP, Holick MF, Hollis BW, Lamberg-Allardt C, McGrath JJ, Norman AW, Scragg R, Whiting SJ, Willett WC, Zittermann A: The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr. 2007, 85: 649-650.PubMed Vieth R, Bischoff-Ferrari H, Boucher BJ, Dawson-Hughes B, Garland CF, Heaney RP, Holick MF, Hollis BW, Lamberg-Allardt C, McGrath JJ, Norman AW, Scragg R, Whiting SJ, Willett WC, Zittermann A: The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr. 2007, 85: 649-650.PubMed
16.
go back to reference Sneve M, Figenschau Y, Jorde R: Supplementation with cholecalciferol does not result in weight reduction in overweight and obese subjects. Eur J Endocrinol. 2008, 159: 675-684. 10.1530/EJE-08-0339.CrossRefPubMed Sneve M, Figenschau Y, Jorde R: Supplementation with cholecalciferol does not result in weight reduction in overweight and obese subjects. Eur J Endocrinol. 2008, 159: 675-684. 10.1530/EJE-08-0339.CrossRefPubMed
17.
go back to reference Kamycheva E, Jorde R, Figenschau Y, Haug E: Insulin sensitivity in subjects with secondary hyperparathyroidism and the effect of a low serum 25-hydroxyvitamin D level on insulin sensitivity. J Endocrinol Invest. 2007, 30: 126-132.CrossRefPubMed Kamycheva E, Jorde R, Figenschau Y, Haug E: Insulin sensitivity in subjects with secondary hyperparathyroidism and the effect of a low serum 25-hydroxyvitamin D level on insulin sensitivity. J Endocrinol Invest. 2007, 30: 126-132.CrossRefPubMed
18.
go back to reference Osmancevic A, Nilsen LT, Landin-Wilhelmsen K, Søyland E, Abusdal Torjesen P, Hagve TA, Nenseter MS, Krogstad AL: Effect of climate therapy at Gran Canaria on vitamin D production, blood glucose and lipids in patients with psoriasis. J Eur Acad Dermatol Venereol. 2009, 23: 1133-1140. 10.1111/j.1468-3083.2009.03245.x.CrossRefPubMed Osmancevic A, Nilsen LT, Landin-Wilhelmsen K, Søyland E, Abusdal Torjesen P, Hagve TA, Nenseter MS, Krogstad AL: Effect of climate therapy at Gran Canaria on vitamin D production, blood glucose and lipids in patients with psoriasis. J Eur Acad Dermatol Venereol. 2009, 23: 1133-1140. 10.1111/j.1468-3083.2009.03245.x.CrossRefPubMed
19.
go back to reference Vik A, Mathiesen EB, Notø AT, Sveinbjørnsson B, Brox J, Hansen JB: Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans. Atherosclerosis. 2007, 191: 128-134. 10.1016/j.atherosclerosis.2006.03.002.CrossRefPubMed Vik A, Mathiesen EB, Notø AT, Sveinbjørnsson B, Brox J, Hansen JB: Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans. Atherosclerosis. 2007, 191: 128-134. 10.1016/j.atherosclerosis.2006.03.002.CrossRefPubMed
20.
go back to reference von Mühlen D, Greendale G, Garland C, Wan L, Barrett-Connor E: Vitamin D, parathyroid hormone levels and bone mineral density in community-dwelling older women: The Rancho Bernardo Study. Osteoporosis International. 2005, 16: 1721-1726. 10.1007/s00198-005-1910-8.CrossRefPubMed von Mühlen D, Greendale G, Garland C, Wan L, Barrett-Connor E: Vitamin D, parathyroid hormone levels and bone mineral density in community-dwelling older women: The Rancho Bernardo Study. Osteoporosis International. 2005, 16: 1721-1726. 10.1007/s00198-005-1910-8.CrossRefPubMed
21.
go back to reference Sneve M, Emaus N, Joakimsen RM, Jorde R: The association between serum parathyroid hormone and bone mineral density, and the impact of smoking: the Tromso Study. Eur J Endocrinol. 2008, 158: 401-409. 10.1530/EJE-07-0610.CrossRefPubMed Sneve M, Emaus N, Joakimsen RM, Jorde R: The association between serum parathyroid hormone and bone mineral density, and the impact of smoking: the Tromso Study. Eur J Endocrinol. 2008, 158: 401-409. 10.1530/EJE-07-0610.CrossRefPubMed
22.
go back to reference Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R, Austrian Study Group on Normative Values of Bone Metabolism: Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone. 2003, 32: 681-686. 10.1016/S8756-3282(03)00090-5.CrossRefPubMed Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R, Austrian Study Group on Normative Values of Bone Metabolism: Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone. 2003, 32: 681-686. 10.1016/S8756-3282(03)00090-5.CrossRefPubMed
23.
go back to reference Indridason OS, Franzson L, Sigurdsson G: Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int. 2005, 16: 417-423. 10.1007/s00198-004-1699-x.CrossRefPubMed Indridason OS, Franzson L, Sigurdsson G: Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int. 2005, 16: 417-423. 10.1007/s00198-004-1699-x.CrossRefPubMed
24.
go back to reference Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B: Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006, 84: 18-28.PubMed Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B: Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006, 84: 18-28.PubMed
25.
go back to reference Zittermann A: Vitamin D and disease prevention with special reference to cardiovascular disease. Progress in Biophysics and Molecular Biology. 2006, 92: 39-48. 10.1016/j.pbiomolbio.2006.02.001.CrossRefPubMed Zittermann A: Vitamin D and disease prevention with special reference to cardiovascular disease. Progress in Biophysics and Molecular Biology. 2006, 92: 39-48. 10.1016/j.pbiomolbio.2006.02.001.CrossRefPubMed
26.
go back to reference Lee SK, Lorenzo JA: Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology. 1999, 140: 3552-3561. 10.1210/en.140.8.3552.PubMed Lee SK, Lorenzo JA: Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology. 1999, 140: 3552-3561. 10.1210/en.140.8.3552.PubMed
27.
go back to reference Rogers A, Eastell R: Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab. 2005, 90: 6323-6331. 10.1210/jc.2005-0794.CrossRefPubMed Rogers A, Eastell R: Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab. 2005, 90: 6323-6331. 10.1210/jc.2005-0794.CrossRefPubMed
28.
go back to reference Crisafulli A, Altavilla D, Squadrito G, Romeo A, Adamo EB, Marini R, Inferrera MA, Marini H, Bitto A, D'Anna R, Corrado F, Bartolone S, Frisina N, Squadrito F: Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women. J Clin Endocrinol Metab. 2004, 89: 188-192. 10.1210/jc.2003-030891.CrossRefPubMed Crisafulli A, Altavilla D, Squadrito G, Romeo A, Adamo EB, Marini R, Inferrera MA, Marini H, Bitto A, D'Anna R, Corrado F, Bartolone S, Frisina N, Squadrito F: Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women. J Clin Endocrinol Metab. 2004, 89: 188-192. 10.1210/jc.2003-030891.CrossRefPubMed
29.
go back to reference Hofbauer LC, Schoppet M, Schüller P, Viereck V, Christ M: Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. Clin Endocrinol. 2004, 60: 214-219. 10.1046/j.1365-2265.2003.01969.x.CrossRef Hofbauer LC, Schoppet M, Schüller P, Viereck V, Christ M: Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. Clin Endocrinol. 2004, 60: 214-219. 10.1046/j.1365-2265.2003.01969.x.CrossRef
30.
go back to reference Alvarez L, Peris P, Guañabens N, Vidal S, Ros I, Pons F, Filella X, Monegal A, Muñoz-Gomez J, Ballesta AM: Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Arthritis Rheum. 2003, 48: 824-828. 10.1002/art.10834.CrossRefPubMed Alvarez L, Peris P, Guañabens N, Vidal S, Ros I, Pons F, Filella X, Monegal A, Muñoz-Gomez J, Ballesta AM: Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Arthritis Rheum. 2003, 48: 824-828. 10.1002/art.10834.CrossRefPubMed
31.
go back to reference Valleala H, Mandelin J, Laasonen L, Koivula MK, Risteli J, Konttinen YT: Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. Eur J Endocrinol. 2003, 148: 527-530. 10.1530/eje.0.1480527.CrossRefPubMed Valleala H, Mandelin J, Laasonen L, Koivula MK, Risteli J, Konttinen YT: Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. Eur J Endocrinol. 2003, 148: 527-530. 10.1530/eje.0.1480527.CrossRefPubMed
32.
go back to reference Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL: Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 1999, 140: 4367-4370. 10.1210/en.140.9.4367.PubMed Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL: Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 1999, 140: 4367-4370. 10.1210/en.140.9.4367.PubMed
33.
go back to reference Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Gründker C, Hofbauer LC: Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun. 2002, 291: 680-686. 10.1006/bbrc.2002.6510.CrossRefPubMed Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Gründker C, Hofbauer LC: Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun. 2002, 291: 680-686. 10.1006/bbrc.2002.6510.CrossRefPubMed
Metadata
Title
No significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year
Authors
Rolf Jorde
Monica Sneve
Peter A Torjesen
Yngve Figenschau
John-Bjarne Hansen
Guri Grimnes
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Nutrition Journal / Issue 1/2010
Electronic ISSN: 1475-2891
DOI
https://doi.org/10.1186/1475-2891-9-1

Other articles of this Issue 1/2010

Nutrition Journal 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.